TABLE 1.
Demographic information of P. falciparum patients involved in three clinical efficacy studies of artemisinin drugs conducted between 2008 and 2013 at the China-Myanmar border
| Parameter | Value(s) for study: |
||
|---|---|---|---|
| 1 (2008; DPa) | 2 (2009–2010; artesunateb) | 3 (2012–2013; DPa) | |
| Patient data | |||
| Febrile patients screened (no.) | 1,073 | 1,095 | 9,044 |
| P. falciparum patients identified (no.) | 91 | 65 | 142 |
| P. falciparum patients recruited (no.) | 74 | 65 | 109 |
| Completed 28-day follow-up (no.) | 64 | 47 | 71 |
| Age (yr) | 2–60 | 3–58 | 1–60 |
| Male:female | 54:20 | 48:17 | 66:43 |
| Mean (range) day 0 asexual parasite density (/μl) | 16,666 (560–625,040) | 60,351 (1,004–657,818) | 3,905 (140–147,600) |
| Day 28 ACPR (%) | 100 | 95.9 (1 LCF, 1 LPF) | 100c |
| Parasite positivity,d n (%) | |||
| Day 1 | 21 (32.8) | 52 (80) | 32 (45.1) |
| Day 2 | 11 (17.2) | 27 (41.5) | 18 (25.4) |
| Day 3 | 4 (6.3) | 15 (23.1) | 5 (7.0) |
a
A concentration of ∼6 mg/kg of body weight of DHA in 4 doses in 2 days was used.
b
Artesunate was used at 16 mg/kg for 7 days.
c
Day 42 follow-up with 100% ACPR.
d
Parasite positivity rates were calculated using patients available on each date instead of patient numbers who completed the 28-day follow-up.